Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently Amended) A compound of formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and
n is an integer of from 3 to 11;
with the proviso that m + n is 5 to 19;

R^1 is SR^6, SOR^6, or SO_2R^6,
wherein R^6 is a C_{3-7}cycloalkyl or C_{3-7}cycloalkenyl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl;

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;

Ar is a group selected from



(a)



(b)



(c)

and



(d)

wherein R^8 represents hydrogen, halogen, $-(CH_2)_qOR^{11}$, $-NR^{11}C(O)R^{12}$, $-NR^{11}SO_2R^{12}$, $-SO_2NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$, and R^7 represents hydrogen, halogen, or C_{1-4} alkyl;

or R^8 represents $-NHR^{14}$ and R^7 and $-NHR^{14}$ together form a 5- or 6-membered heterocyclic ring;

R^9 represents hydrogen, halogen, $-OR^{11}$ or $-NR^{11}R^{12}$;

R^{10} represents hydrogen, halogen, haloC_{1-4} alkyl, $-OR^{11}$, $-NR^{11}R^{12}$, $-OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$;

R^{11} and R^{12} each independently represents hydrogen or C_{1-4} alkyl, or in the groups $-NR^{11}R^{12}$, $-SO_2NR^{11}R^{12}$ and $-OC(O)NR^{11}R^{12}$, R^{11} and R^{12}

independently represent hydrogen or C_{1-4} alkyl or together with the nitrogen atom to which they are attached form a 5-, 6- or 7- membered nitrogen-containing ring,

R^{13} represents an aryl ~~(eg phenyl or naphthyl)~~ group which may be unsubstituted or substituted by one or more substituents selected from halogen, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy or halo C_{1-4} alkyl; and

q is zero or an integer from 1 to 4.

2. (Currently Amended) A compound according to Claim 1 ~~of formula (I) or a salt, solvate of physiologically functional derivative thereof,~~ wherein ~~formula (I) is as defined in claim, except that~~ R^8 is selected from the group consisting of halogen, $-(CH_2)_qOR^{11}$, $-NR^{11}C(O)R^{12}$, $-NR^{11}SO_2R^{12}$, $-SO_2NR^{11}R^{12}$, $-NR^{11}R^{12}$, $-OC(O)R^{13}$ or $OC(O)NR^{11}R^{12}$, and $-NHR^{14}$ and R^7 and $-NHR^{14}$ together form a 5- or 6- membered heterocyclic ring ~~does not represent hydrogen~~.

3. (Currently Amended) A compound according to claim 1 ~~or claim 2~~ wherein R^1 represents $-SO_2R^6$.

4. (Currently Amended) A compound according to claim 1 ~~any of claims 1 to 3~~ wherein R^6 represents a C_{3-7} cycloalkyl group.

5. (Currently Amended) A compound according to claim 1 ~~any of claims 1 to 4~~ wherein R^2 and R^3 each represent hydrogen.

6. (Currently Amended) A compound according to claim 1 ~~any of claims 1 to 5~~ wherein R^4 and R^5 are independently selected from hydrogen and methyl.

7. (Currently Amended) A compound according to claim 1 ~~any of claims 1 to 6~~ wherein Ar is selected from a group (a) or (b):



(a)



(b)

8. (Original) A compound of formula (Ia):



(Ia)

or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8; and
n is an integer of from 3 to 11;
with the proviso that m + n is 5 to 19;

R^1 is SR^6, SOR^6, or SO_2R^6,
wherein R^6 is a C_{3-7}cycloalkyl or C_{3-7}cycloalkenyl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl; and

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4.

9. (Currently Amended) A compound according to claim 1 ~~any of claims~~

~~1 to 8~~ wherein m is 5 or 6 and n is 3 or 4.

10. (Currently Amended) A compound ~~of formula (I) or (Ia)~~ selected from:
4-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfinyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol;
4-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfinyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (Isomer 1);
4-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfinyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (Isomer 2);
4-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol;
4-{(1*R*)-2-[(6-{4-[4-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol;
4-((1*R*)-2-{[6-({4-[3-(Cyclohexylsulfonyl)phenyl]butyl}oxy)hexyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
4-((1*R*)-2-{[6-({4-[3-(3-Cyclopenten-1-ylsulfonyl)phenyl]butyl}oxy)hexyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
4-((1*R*)-2-{[6-({5-[3-(Cyclopentylsulfonyl)phenyl]pentyl}oxy)hexyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
4-((1*R*)-2-{[7-({3-[3-(Cyclopentylsulfonyl)phenyl]propyl}oxy)heptyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
4-((1*R*)-2-{[6-({4-[3-(Cyclopentylsulfonyl)-5-methylphenyl]butyl}oxy)hexyl]amino}-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
N-[5-((1*R*)-2-{[6-({4-[3-(Cyclopentylsulfonyl)phenyl]butyl}oxy)hexyl]amino}-1-hydroxyethyl)-2-hydroxyphenyl]methanesulfonamide;
4-((1*R*)-2-{[6-({4-[3-(Cyclopentylsulfonyl)phenyl]butyl}oxy)hexyl]amino}-1-hydroxyethyl)-2-fluorophenol;
6-{2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)pyridin-3-ol;
5-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-8-hydroxy-3,4-dihydroquinolin-2(1*H*)-one;
5-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-hydroxyphenylformamide;

and salts, solvates, and physiologically functional derivatives thereof.

11. (Currently Amended) A compound according to claim 10 ~~of formula (I) or (Ia)~~ which is:
4-{(1*R*)-2-[(6-{4-[3-(Cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol;
or a salt, solvate, or physiologically functional derivative thereof.

12. (Currently Amended) A compound according to claim 1 ~~any of claims 1 to 11~~ in the form of a salt formed with an arylsulphonic acid.

13. (Currently Amended) A compound according to ~~any of~~ claim 8~~, claim 9 or claim 12~~ which is selected from:
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol 4-methylbenzenesulfonate;
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol 4-bromobenzene sulfonate;
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol 4-chlorobenzene sulfonate
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol 3-toluene sulfonate;
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol 4-biphenyl sulfonate; and
4-{(1*R*)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy} hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol, naphthalene-2-sulfonate.

14. (Original) A compound according to claim 13 wherein the salt is in crystalline form.

15. (Currently Amended) A method for the prophylaxis or treatment of a clinical condition in a mammal~~, such as a human,~~ for which a selective β_2-adrenoreceptor agonist is indicated, which comprises administering

~~administration of~~ a therapeutically effective amount of a compound ~~of formula (I) or (Ia)~~ according to claim 1 ~~any of claims 1 to 14~~ or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

16. (Canceled)

17. (Currently Amended) A pharmaceutical formulation comprising a compound according to claim 1 ~~of formula (I) or (Ia) according to any of claims 1 to 14~~ or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

18. (Currently Amended) A combination comprising a compound according to claim 1 ~~of formula (I) or (Ia) according to any of claims 1 to 14~~ or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and one or more other therapeutic ingredients.

19. (Canceled).

20. (Currently Amended) A process for the preparation of a compound ~~of formula (I) or (Ia)~~ according to claim 1 ~~any of claims 1 to 14~~ or a salt, solvate, or physiologically functional derivative thereof, which comprises:

~~(a)~~ deprotecting ~~deprotection of~~ a protected intermediate~~, for example~~ of formula (II):



(II)

or a salt or solvate thereof, wherein R^1, R^2, R^3, R^4, R^5, m, and n are as defined for the compound of formula (I), R^{19} represents an optionally protected form of

Ar; and R^{20} and R^{21} are each independently either hydrogen or a protecting group, provided that the compound of formula (II) contains at least one protecting group;

~~(a) reaction of a compound of formula (X):~~



(X)

~~wherein R^2, R^3, R^4, R^5, R^{19}, R^{20}, R^{21}, m and n are as defined for formula (II) each R^{26} independently represents hydrogen or C_{1-4}alkyl, and x and y each represent 0, 1 or 2;~~
~~to effect ring closure;~~

~~(c) alkylation of an amine of formula (XIII):~~



(XIII)

~~wherein R^{22}, R^{23}, R^{20} and R^{21} are each independently either hydrogen or a protecting group with a compound of formula (XVII):~~



(XVII)

wherein R^1, R^2, R^3, R^4, R^5, m, and n are as defined for the compound of formula (I) and L^1 is a leaving group;

(d) reduction of a compound of formula (XIX):



(XIX)

Wherein R^1, R^2, R^3, R^4, R^5, m and n are as defined for formula (I), R^{19} represents an optionally protected form of Ar and R^{20} and R^{21} are each independently hydrogen or a protecting group as defined above.

(e) reacting a compound of formula (XXIII):



(XXIII)

wherein R^{19} is as hereinbefore defined and L^3 is a leaving group as defined above for
L^1 or L^2;

or a compound of formula (XXIV):



(XXIV)

~~wherein R^{19} is as hereinbefore defined~~

~~with an amine of formula (XXV):~~



(XXV)

~~wherein R^1, R^2, R^3, R^4, R^5, R^{20}, m and n are as defined for formula (II); or~~

~~(f) removal of a chiral auxiliary from a compound of folrmula (IIa)~~



(IIa)

~~wherein R^1 — R^5, m and n are as defined for formula (I), R^{19} represents an optionally protected form of Ar, R^{21} represent hydrogen or a protecting group and R^{27} represents a chiral auxiliary.~~

optionally followed by one or more of the following steps in any order selected from the group consisting of:

(i) removing ~~optional removal of~~ any protecting groups;

(ii) separating ~~optional separation of~~ an enantiomer from a mixture of enantiomers;

(iii) converting ~~optional conversion of~~ one compound of formula (I) to a different compound of formula (I) ~~eg. conversion of a compound~~ wherein R^1 is SR^6 to a compound wherein R^1 is SOR^6 or SO_2R^6, or conversion of a compound wherein R^1 is SOR^6 to a compound wherein R^1 is SO_2R^6;

(iv) converting ~~optional conversion of~~ a compound wherein R^6 represents cycloalkenyl to a compound wherein R^6 represents cycloalkyl, eg. by hydrogenation; and

(v) converting ~~optional conversion of~~ the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

21. (Canceled)

22. (New) A compound according to claim 1, wherein R^{13} is a phenyl group.

23. (New) A compound according to claim 1, wherein R^{13} is a naphthyl group.

24. (New) A method according to claim 15, wherein the mammal is a human.

25. (New) A process for the preparation of a compound according to claim 1 or a salt, solvate, or physiologically functional derivative thereof, which comprises:

reacting a compound of formula (X):



(X)

wherein R^1, R^2, R^3, R^4, R^5, m, and n are as defined for the compound of formula (I), R^{19} represents an optionally protected form of Ar; and R^{20} and R^{21} are each independently either hydrogen or a protecting group, each R^{26} independently represents hydrogen or C_{1-4}alkyl, and x and y each represent 0, 1 or 2; to effect ring closure;

optionally followed by one or more of the following steps in any order selected from the group consisting of:

(i) removing any protecting groups;

(ii) separating an enantiomer from a mixture of enantiomers;

(iii) converting one compound of formula (I) to a different compound of formula wherein R^1 is SR^6 to a compound wherein R^1 is SOR^6 or SO_2R^6, or conversion of a compound wherein R^1 is SOR^6 to a compound wherein R^1 is SO_2R^6;

(iv) converting a compound wherein R^6 represents cycloalkenyl to a compound wherein R^6 represents cycloalkyl, eg. by hydrogenation; and

(v) converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

26. (New) A process for the preparation of a compound according to claim 1 or a salt, solvate, or physiologically functional derivative thereof, which comprises:

alkylating an amine of formula (XIII):



(XIII)

wherein R^{22}, R^{23}, R^{20} and R^{21} are each independently either hydrogen or a protecting group with a compound of formula (XVII):



(XVII)

wherein R^1, R^2, R^3, R^4, R^5, m, and n are as defined for the compound of formula (I) and L^1 is a leaving group;

optionally followed by one or more of the following steps in any order selected from the group consisting of:

(i) removing any protecting groups;

(ii) separating an enantiomer from a mixture of enantiomers;

(iii) converting one compound of formula (I) to a different compound of formula (I) wherein R^1 is SR^6 to a compound wherein R^1 is SOR^6 or SO_2R^6, or conversion of a compound wherein R^1 is SOR^6 to a compound wherein R^1 is SO_2R^6;

(iv) converting a compound wherein R^6 represents cycloalkenyl to a compound wherein R^6 represents cycloalkyl, eg. by hydrogenation; and

(v) converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

27. (New) A process for the preparation of a compound according to claim 1 or a salt, solvate, or physiologically functional derivative thereof, which comprises:

reducing a compound of formula (XIX):



(XIX)

Wherein R^1, R^2, R^3, R^4, R^5, m and n are as defined for formula (I), R^{19} represents an optionally protected form of Ar and R^{20} and R^{21} are each independently hydrogen or a protecting group

optionally followed by one or more of the following steps in any order selected from the group consisting of:

(i) removing any protecting groups;

(ii) separating an enantiomer from a mixture of enantiomers;

(iii) converting one compound of formula (I) to a different compound of formula (I) wherein R^1 is SR^6 to a compound wherein R^1 is SOR^6 or SO_2R^6, or conversion of a compound wherein R^1 is SOR^6 to a compound wherein R^1 is SO_2R^6;

(iv) converting a compound wherein R^6 represents cycloalkenyl to a compound wherein R^6 represents cycloalkyl, eg. by hydrogenation; and

(v) converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

28. (New) A process for the preparation of a compound according to claim 1 or a salt, solvate, or physiologically functional derivative thereof, which comprises:

reacting a compound of formula (XXIII):



(XXIII)

wherein R^{19} is as hereinbefore defined and L^3 is a leaving group as defined above for
L^1 or L^2;

or a compound of formula (XXIV):



(XXIV)

with an amine of formula (XXV):
wherein R^1, R^2, R^3, R^4, R^5, m, and n are as defined for the compound of formula (I), R^{19} represents an optionally protected form of Ar; and R^{20} and R^{21} are each independently either hydrogen or a protecting group

optionally followed by one or more of the following steps in any order selected from the group consisting of:

(i) removing any protecting groups;

(ii) separating an enantiomer from a mixture of enantiomers;

(iii) converting one compound of formula (I) to a different compound of formula (I) wherein R^1 is SR^6 to a compound wherein R^1 is SOR^6 or SO_2R^6, or conversion of a compound wherein R^1 is SOR^6 to a compound wherein R^1 is SO_2R^6;

(iv) converting a compound wherein R^6 represents cycloalkenyl to a compound wherein R^6 represents cycloalkyl, eg. by hydrogenation; and

(v) converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

29. (New) A process for the preparation of a compound according to claim 1 or a salt, solvate, or physiologically functional derivative thereof, which comprises:

removing a chiral auxiliary from a compound of folrmula (IIa)



(IIa)

wherein $R^1 - R^5$, m and n are as defined for formula (I), R^{19} represents an optionally protected form of Ar, R^{21} represent hydrogen or a protecting group and R^{27} represents a chiral auxiliary

optionally followed by one or more of the following steps in any order selected from the group consisting of:

(i) removing any protecting groups;

(ii) separating an enantiomer from a mixture of enantiomers;

(iii) converting one compound of formula (I) to a different compound of formula (I) eg. conversion of a compound wherein R^1 is SR^6 to a compound wherein R^1 is SOR^6 or SO_2R^6, or conversion of a compound wherein R^1 is SOR^6 to a compound wherein R^1 is SO_2R^6;

(iv) converting a compound wherein R^6 represents cycloalkenyl to a compound wherein R^6 represents cycloalkyl, eg. by hydrogenation; and

(v) converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

30. (New) A compound of the formula (II):



(II)

wherein m is an integer of from 2 to 8; and

n is an integer of from 3 to 11;

with the proviso that m + n is 5 to 19;

R^1 is SR^6, SOR^6, or SO_2R^6,
wherein R^6 is a C_{3-7}cycloalkyl or C_{3-7}cycloalkenyl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl;

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;
R^{19} represents an optionally protected form of Ar; and R^{20} and R^{21} are each independently either hydrogen or a protecting group;

31. (New) A compound of the formula (III):



(III)

or a salt or solvate thereof,
wherein m is an integer of from 2 to 8; and
n is an integer of from 3 to 11;
with the proviso that m + n is 5 to 19;

R^1 is SR^6, SOR^6, or SO_2R^6,
wherein R^6 is a C_{3-7}cycloalkyl or C_{3-7}cycloalkenyl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl;

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;

R^{19} represents an optionally protected form of Ar;
R^{20} and R^{21} are each independently either hydrogen or a protecting group.
and R^{24} and R^{25} are independently selected from hydrogen,
C_{1-6}alkyl, or aryl or R^{24} and R^{25} together form a C_{3-7} alkyl group.

32. (New) A compound of the formula (IV):



(IV)

or a salt or solvate thereof, wherein
wherein m is an integer of from 2 to 8; and
n is an integer of from 3 to 11;
with the proviso that m + n is 5 to 19;

R^1 is SR^6, SOR^6, or SO_2R^6,
wherein R^6 is a C_{3-7}cycloalkyl or C_{3-7}cycloalkenyl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl;

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4; and R^{19} represents an optionally protected form of Ar.

33. (New) A compound of formula (X):



(X)

wherein m is an integer of from 2 to 8; and
n is an integer of from 3 to 11;
with the proviso that m + n is 5 to 19;

R^1 is SR^6, SOR^6, or SO_2R^6,
wherein R^6 is a C_{3-7}cycloalkyl or C_{3-7}cycloalkenyl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl;

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;
R^{19} represents an optionally protected form of Ar;
R^{20} and R^{21} are each independently either hydrogen or a protecting group.
and each R^{26} independently represents hydrogen or C_{1-4}alkyl, and x and y each represent 0, 1 or 2; by effecting ring closure to form a cycloalkenyl group.

34. (New) A compound of the formula (XIX):



(XIX)

wherein m is an integer of from 2 to 8; and
n is an integer of from 3 to 11;
with the proviso that m + n is 5 to 19;

R^1 is SR^6, SOR^6, or SO_2R^6,
wherein R^6 is a C_{3-7}cycloalkyl or C_{3-7}cycloalkenyl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkoxy, halo, phenyl, and C_{1-6}haloalkyl;

R^4 and R^5 are independently selected from hydrogen and C_{1-4}alkyl with the proviso that the total number of carbon atoms in R^4 and R^5 is not more than 4;
R^{19} represents an optionally protected form of Ar;
R^{20} and R^{21} are each independently either hydrogen or a protecting group.